YD Bio (YDESW) Other Non-Current Assets (2024 - 2026)
YD Bio's (YDESW) quarterly Other Non-Current Assets came in at $1.9 million in Q2 2026, up 32.83% year-over-year from $1.5 million in Q2 2025, and up 35.36% quarter-over-quarter from $1.4 million in Q4 2025.
Analysis
YD Bio (YDESW) Other Non-Current Assets (2024 - 2026) Analysis & Trends
YD Bio (YDESW) has reported Other Non-Current Assets for 3 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Assets rose 32.83% year-over-year to $1.9 million in Q2 2026; TTM through Jun 2026 was $1.9 million, a 32.83% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, up 127.89% from the prior year.
- Other Non-Current Assets was $1.9 million for Q2 2026 at YD Bio, up from $1.4 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.9 million in Q2 2026 and troughed at $628232.0 in Q4 2024.
- A 3-year average of $1.4 million and a median of $1.4 million in 2025 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 127.89% in 2025 and soared 32.83% in 2026, its largest moves.
- Over 3 years, Other Non-Current Assets stood at $628232.0 in 2024, then jumped by 127.89% to $1.4 million in 2025, then soared by 35.36% to $1.9 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.9 million (Q2 2026), $1.4 million (Q4 2025), and $1.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.55 Bn | 197.56 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 181.17 Bn | 177.99 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.18 Bn | 124.33 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.66 Bn | 56.48 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.17 Bn | 30.86 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 30.04 Bn | 30.04 Bn | 1.16 Mn | 29.59 Mn |
| 10 | YD Bio | 29.02 Mn | 26.36 Mn | - | 1.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Dec 31, 2024 | 628,232.00 |